Someone posted the following on Yahoo Msg Board, I thought it is interesting -
My reaction is to check and check again. We are waiting for a large BARDA grant. Manufacture of the Il-key peptide link is happening now. There can only be one reason and that has to be we are close in the running with a BARDA grant towards a C-19 vaccine award. Not trusting, I checked with BARDA via a site called "DECIDER" and for sure we, among others, are listed. GNBT success with the xxx breast cancer vaccine and our association with companies and professionals of note most likely assures a grant is forthcoming. Further this is to say nothing of the GNBT key peptide link, its success and ability to bind to and nullify the attachment effect of the C-19 virus to body cells, notably lung tissue. Papers and notable recommendations sent with the application greatly, in my opinion, improves, and virtually guarantees our award success based on historical success and merit. Stock has his $.80 / share. Considering the new manufacture of our peptide link and the incredible Excellagen, I see this OTC stock as grossly undervalued. In the short term, especially with success in a BARDA grant, it might easily reach $100.00 / share, making $ .74, or anything less than $1,00 value, a gift. Check out BARDA site via "DECIDER" and see for yourself. We are THERE.
Obviously, when the BARDA grant is awarded, GNBT will qualify to be uplisted to the NASDAQ where it will be scrutinized by multiple evaluators and its true potential and value will be more accurately assessed. Please hold on. While it may be tempting to take a short sighted profit, especially for those who bought while in the $ .40 range, I would simply hold my position because I expect very much higher valuations. I am not selling at all. I believe that current GNBT products and those in development will show how grossly undervalued GNBT is and would still be a bargain even at $1.00 / share!
My reaction is to check and check again. We are waiting for a large BARDA grant. Manufacture of the Il-key peptide link is happening now. There can only be one reason and that has to be we are close in the running with a BARDA grant towards a C-19 vaccine award. Not trusting, I checked with BARDA via a site called "DECIDER" and for sure we, among others, are listed. GNBT success with the xxx breast cancer vaccine and our association with companies and professionals of note most likely assures a grant is forthcoming. Further this is to say nothing of the GNBT key peptide link, its success and ability to bind to and nullify the attachment effect of the C-19 virus to body cells, notably lung tissue. Papers and notable recommendations sent with the application greatly, in my opinion, improves, and virtually guarantees our award success based on historical success and merit. Stock has his $.80 / share. Considering the new manufacture of our peptide link and the incredible Excellagen, I see this OTC stock as grossly undervalued. In the short term, especially with success in a BARDA grant, it might easily reach $100.00 / share, making $ .74, or anything less than $1,00 value, a gift. Check out BARDA site via "DECIDER" and see for yourself. We are THERE.
Obviously, when the BARDA grant is awarded, GNBT will qualify to be uplisted to the NASDAQ where it will be scrutinized by multiple evaluators and its true potential and value will be more accurately assessed. Please hold on. While it may be tempting to take a short sighted profit, especially for those who bought while in the $ .40 range, I would simply hold my position because I expect very much higher valuations. I am not selling at all. I believe that current GNBT products and those in development will show how grossly undervalued GNBT is and would still be a bargain even at $1.00 / share!
3
